JP2015518006A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015518006A5 JP2015518006A5 JP2015514242A JP2015514242A JP2015518006A5 JP 2015518006 A5 JP2015518006 A5 JP 2015518006A5 JP 2015514242 A JP2015514242 A JP 2015514242A JP 2015514242 A JP2015514242 A JP 2015514242A JP 2015518006 A5 JP2015518006 A5 JP 2015518006A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- allergic condition
- composition
- hydrochloride
- performed via
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010027654 Allergic conditions Diseases 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 6
- 229960004335 Azelastine hydrochloride Drugs 0.000 claims 2
- IMZMKUWMOSJXDT-UHFFFAOYSA-N Cromoglicic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N Mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims 2
- 229940100656 Nasal Solution Drugs 0.000 claims 2
- 210000001331 Nose Anatomy 0.000 claims 2
- 229960005162 Oxymetazoline hydrochloride Drugs 0.000 claims 2
- 229960003733 Phenylephrine Hydrochloride Drugs 0.000 claims 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 2
- SRBFZHDQGSBBOR-SQOUGZDYSA-N Xylose Natural products O[C@@H]1CO[C@@H](O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-SQOUGZDYSA-N 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- YEJAJYAHJQIWNU-UHFFFAOYSA-N azelastine hydrochloride Chemical compound Cl.C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 YEJAJYAHJQIWNU-UHFFFAOYSA-N 0.000 claims 2
- 229960000265 cromoglicic acid Drugs 0.000 claims 2
- 229960002744 mometasone furoate Drugs 0.000 claims 2
- BEEDODBODQVSIM-UHFFFAOYSA-N oxymetazoline hydrochloride Chemical compound Cl.CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 BEEDODBODQVSIM-UHFFFAOYSA-N 0.000 claims 2
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 claims 2
- HEBKCHPVOIAQTA-QWWZWVQMSA-N Arabitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-Threitol Natural products OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 claims 1
- 239000004386 Erythritol Substances 0.000 claims 1
- 229940009714 Erythritol Drugs 0.000 claims 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N Erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims 1
- 210000001508 Eye Anatomy 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N Maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 210000000214 Mouth Anatomy 0.000 claims 1
- 229940097496 Nasal Spray Drugs 0.000 claims 1
- 206010028740 Nasal dryness Diseases 0.000 claims 1
- 210000003800 Pharynx Anatomy 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 Xylitol Drugs 0.000 claims 1
- 229960003487 Xylose Drugs 0.000 claims 1
- 230000001070 adhesive Effects 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 238000002716 delivery method Methods 0.000 claims 1
- 235000019414 erythritol Nutrition 0.000 claims 1
- 239000000845 maltitol Substances 0.000 claims 1
- 235000010449 maltitol Nutrition 0.000 claims 1
- 229940035436 maltitol Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 229960001855 mannitol Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000007922 nasal spray Substances 0.000 claims 1
- -1 tivitol Chemical compound 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
Claims (9)
- ヒトにおけるアレルギー状態を治療する方法であって、以下の工程、
アレルギー状態を有するヒトを同定する工程、及び
アレルギー状態を有する前記ヒトに、クロモグリク酸ナトリウム、塩酸フェニレフリン、塩酸オキシメタゾリン、塩酸アゼラスチン及びフロ酸モメタゾンの少なくとも1つの治療に有効な量から本質的になる組成物を投与して、アレルギー状態を有する前記ヒトの該アレルギー状態を治療する工程であって、前記組成物が、該アレルギー状態を治療するためのクロモグリク酸ナトリウム、塩酸フェニレフリン、塩酸オキシメタゾリン、塩酸アゼラスチン及びフロ酸モメタゾンの前記少なくとも1つによって生じる鼻乾燥を低下するための、キシリトール、エリスリトール、マンニトール、マルチトール、ティビトール、アラビトール、リボース及びキシロースの少なくとも1つの治療に有効な量から更に本質的になる工程、
から本質的になることを特徴とする方法。 - 前記組成物が、水溶液である請求項1に記載の方法。
- アレルギー状態を有する前記ヒトへの投与工程が、前記組成物を、該ヒトの鼻、目、口、及び喉のうちの少なくとも1つに送達することを介して行われる請求項1に記載の方法。
- 前記組成物が、経鼻溶液である請求項1に記載の方法。
- アレルギー状態を有する前記ヒトへの投与工程が、前記ヒトの鼻に前記経鼻溶液を送達することを介して行われる、請求項4に記載の方法。
- 前記組成物が、ゲルである、請求項4に記載の方法。
- アレルギー状態を有する前記ヒトへの投与工程が、ゲルを接着送達方法で送達することを介して行われる、請求項6に記載の方法。
- アレルギー状態を有する前記ヒトへの投与工程が、鼻噴霧瓶、ドロッパ、ミスター、アトマイザー、ブラッシ及びスワブの少なくとも1つを介して行われる請求項1に記載の方法。
- 前記組成物が、自由に流れる低粘度の水溶液である請求項8に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261651741P | 2012-05-25 | 2012-05-25 | |
US61/651,741 | 2012-05-25 | ||
PCT/US2013/042925 WO2013177594A2 (en) | 2012-05-25 | 2013-05-28 | Xylitol-based anti-mucosal compositions and related methods and compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015518006A JP2015518006A (ja) | 2015-06-25 |
JP2015518006A5 true JP2015518006A5 (ja) | 2017-03-23 |
Family
ID=49621806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015514242A Pending JP2015518006A (ja) | 2012-05-25 | 2013-05-28 | キシリトール系の抗粘膜組成物及び関連する方法並びに組成物 |
Country Status (13)
Country | Link |
---|---|
US (3) | US8709508B2 (ja) |
EP (1) | EP2854781A4 (ja) |
JP (1) | JP2015518006A (ja) |
KR (1) | KR20150011807A (ja) |
CN (1) | CN104334164A (ja) |
AU (1) | AU2013266067B2 (ja) |
BR (1) | BR112014029442A2 (ja) |
CA (1) | CA2870158C (ja) |
IL (1) | IL235875A (ja) |
MX (1) | MX2014013998A (ja) |
RU (1) | RU2607892C2 (ja) |
WO (1) | WO2013177594A2 (ja) |
ZA (1) | ZA201408594B (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
US20120225918A1 (en) | 2011-03-03 | 2012-09-06 | Voom, Llc | Compositions and Methods for Non-Surgical Treatment of Ptosis |
CA2870158C (en) | 2012-05-25 | 2017-10-24 | Xlear, Inc. | Xylitol-based anti-mucosal compositions and related methods and compositions |
US10058530B2 (en) | 2012-10-25 | 2018-08-28 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
WO2014066318A1 (en) | 2012-10-25 | 2014-05-01 | The General Hospital Corporation | Combination therapies for the treatment of alzheimer's disease and related disorders |
JP6545148B2 (ja) | 2013-03-13 | 2019-07-17 | フラットリー ディスカバリー ラブ,エルエルシー | ピリダジノン化合物及び嚢胞性線維症の治療のための方法 |
US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
CA2928028A1 (en) | 2013-10-22 | 2015-04-30 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
EP3725311A1 (en) | 2014-02-10 | 2020-10-21 | Respivant Sciences GmbH | Methods for the treatment of lung diseases with mast cell stabilizers |
US20150224077A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Methods for the Treatment of Systemic Disorders Treatable with Mast Cell Stabilizers, including Mast Cell Related Disorders |
US10238625B2 (en) | 2015-08-07 | 2019-03-26 | Respivant Sciences Gmbh | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
WO2018009889A1 (en) * | 2016-07-07 | 2018-01-11 | Xlear, Inc | Antibacterial nasal compositions and related methods |
JP2019524865A (ja) | 2016-08-31 | 2019-09-05 | ザ ジェネラル ホスピタル コーポレイション | 神経変性疾患と関連する神経炎症におけるマクロファージ/ミクログリア |
JP2019528320A (ja) | 2016-08-31 | 2019-10-10 | レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングRespivant Sciences Gmbh | 特発性肺線維症による慢性咳の治療のためのクロモリン組成物 |
EP3522983A4 (en) | 2016-10-07 | 2020-06-03 | Respivant Sciences GmbH | CROMOLYNE-BASED COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS |
CA3070386A1 (en) | 2017-07-20 | 2019-01-24 | Aztherapies, Inc. | Powdered formulations of cromolyn sodium and ibuprofen |
AU2019299347A1 (en) | 2018-07-02 | 2021-01-21 | Aztherapies, Inc. | Powdered formulations of cromolyn sodium and alpha-lactose |
US10799481B1 (en) | 2019-05-06 | 2020-10-13 | Rvl Pharmaceuticals, Inc. | Compositions and methods for treating ocular disorders |
US11602541B2 (en) | 2020-04-24 | 2023-03-14 | Joseph Scivoletto | Nasal spray composition |
WO2022140795A2 (en) * | 2020-12-23 | 2022-06-30 | Spotlight Therapeutics | Nucleic acid binding protein formulations and uses thereof |
CN116211884B (zh) * | 2023-02-16 | 2024-05-17 | 海孵(海南自贸区)医疗科技有限责任公司 | 一种鼻腔喷雾剂及其制备方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01172324A (ja) * | 1987-12-15 | 1989-07-07 | Armour Internatl Co | コレスチラミン組成物及びその製造法 |
JP2824863B2 (ja) * | 1989-07-12 | 1998-11-18 | エーザイ株式会社 | α▲下1▼―ブロッカー点眼剤 |
IL131492A0 (en) * | 1997-04-30 | 2001-01-28 | Warner Lambert Co | Topical nasal antiinflammatory compositions |
US6054143A (en) * | 1998-03-24 | 2000-04-25 | Jones; Alonzo H. | Xylitol delivery |
US6599883B1 (en) | 1998-10-30 | 2003-07-29 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of xylitol |
DE19947234A1 (de) * | 1999-09-30 | 2001-04-05 | Asta Medica Ag | Neue Kombination von Loteprednol und Antihistaminika |
US20040235807A1 (en) * | 2003-05-21 | 2004-11-25 | Weinrich Karl P. | Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea |
MXPA06001776A (es) * | 2003-08-15 | 2007-09-07 | Qlt Usa Inc | Sistema de suministro de farmaco transmucosal biocorrosivo, adhesivo. |
US20060034947A1 (en) | 2004-06-02 | 2006-02-16 | Burr James B | Erythritol compositions for nasopharynx cleansing |
DK2486942T3 (en) * | 2004-11-24 | 2019-01-28 | Meda Pharmaceuticals Inc | COMPOSITIONS CONTAINING AZELASTINE AND PROCEDURES FOR USING IT |
US20060275223A1 (en) | 2005-06-02 | 2006-12-07 | Burr James B | Erythritol compositions for teeth and gums |
US20070286813A1 (en) * | 2006-06-09 | 2007-12-13 | Toutounghi Camille | Nasal formulation |
US20070286812A1 (en) * | 2006-06-09 | 2007-12-13 | Toutounghi Camille | Nasal formulation |
US20100099650A1 (en) * | 2006-10-10 | 2010-04-22 | Knauer Kent A | Nasal spray composition and method for treating rhinitis, sinusitis or both |
DE202010012255U1 (de) * | 2010-09-07 | 2010-11-18 | Krewel Meuselbach Gmbh | Nasenspray |
CA2870158C (en) | 2012-05-25 | 2017-10-24 | Xlear, Inc. | Xylitol-based anti-mucosal compositions and related methods and compositions |
-
2013
- 2013-05-28 CA CA2870158A patent/CA2870158C/en active Active
- 2013-05-28 CN CN201380027507.XA patent/CN104334164A/zh active Pending
- 2013-05-28 KR KR20147031835A patent/KR20150011807A/ko not_active Application Discontinuation
- 2013-05-28 AU AU2013266067A patent/AU2013266067B2/en active Active
- 2013-05-28 RU RU2014147090A patent/RU2607892C2/ru active
- 2013-05-28 JP JP2015514242A patent/JP2015518006A/ja active Pending
- 2013-05-28 EP EP13793355.2A patent/EP2854781A4/en not_active Ceased
- 2013-05-28 BR BR112014029442A patent/BR112014029442A2/pt not_active Application Discontinuation
- 2013-05-28 WO PCT/US2013/042925 patent/WO2013177594A2/en active Application Filing
- 2013-05-28 MX MX2014013998A patent/MX2014013998A/es not_active Application Discontinuation
- 2013-05-28 US US13/903,860 patent/US8709508B2/en active Active
-
2014
- 2014-04-22 US US14/258,993 patent/US9011941B2/en active Active
- 2014-11-21 ZA ZA2014/08594A patent/ZA201408594B/en unknown
- 2014-11-24 IL IL235875A patent/IL235875A/en active IP Right Grant
-
2015
- 2015-01-27 US US14/606,888 patent/US20150140137A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015518006A5 (ja) | ||
US8709508B2 (en) | Xylitol-based anti-mucosal compositions and related methods and compositions | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
EA201491844A1 (ru) | Распыляющие спрей эжекторные механизмы и устройства, выполненные с изоляцией и возможностью управляемого создания заряда на каплях, и нанесение малообъемных доз офтальмологических средств | |
EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
HRP20171739T1 (hr) | Postupci i kompozicije za liječenje simptoma povezanih s posttraumatskim stresnim poremećajem korištenjem ciklobenzaprina | |
ME02495B (me) | Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda | |
MX2015015589A (es) | Composiciones y metodos para el suministro de agentes activos hidrófobos. | |
JP2015534562A5 (ja) | ||
EA201400002A1 (ru) | Способы лечения заболеваний сетчатки | |
HRP20230809T1 (hr) | Liječenje alzheimerove bolesti u određenoj populaciji bolesnika | |
HRP20192010T1 (hr) | Muskarinski antagonisti i njihove kombinacije za liječenje bolesti dišnih puteva kod konja | |
JP2016525548A5 (ja) | ||
WO2010024956A3 (en) | Antihistamine and antihistamine-like nasal application, products, and method | |
CL2012001402A1 (es) | Composicion farmaceutica en suspension oftalmica acuosa de administracion topica que comprende polimero de carboxivinilo, galactomanana, borato, compuesto en nanoparticulas escasamente soluble, agentes para ajustar ph y tonicidad, conservante y quelante; metodo para tratar trastornos oftalmicos, metodo para mantener viscosidad. | |
BR112015007360A2 (pt) | composição farmacêutica, e, método para a preparação de uma droga de combinação | |
CO6400184A2 (es) | Formulaciones galénicas de compuestos orgánicos | |
BR112014005538A2 (pt) | composições aquosas compreendendo arbecacina | |
BR112013019876A2 (pt) | formulação farmacêutica, uso da formulação farmacêutica, frasco e kit | |
JP2016502991A5 (ja) | ||
EA201591415A1 (ru) | Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии | |
CL2015002627A1 (es) | Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol | |
BR112015030341A2 (pt) | formulações de nanoparticulado e processo para prepará-las, composição farmacêutica e uso de composto ou seu sal farmaceuticamente aceitável e estabilizante de superfície | |
JP2014530847A5 (ja) |